These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18587005)

  • 1. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy.
    Saresella M; Marventano I; Longhi R; Lissoni F; Trabattoni D; Mendozzi L; Caputo D; Clerici M
    FASEB J; 2008 Oct; 22(10):3500-8. PubMed ID: 18587005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
    Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
    J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
    J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
    Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
    Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
    de Andrés C; Aristimuño C; de Las Heras V; Martínez-Ginés ML; Bartolomé M; Arroyo R; Navarro J; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
    J Neuroimmunol; 2007 Jan; 182(1-2):204-11. PubMed ID: 17157927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis.
    Kumar M; Putzki N; Limmroth V; Remus R; Lindemann M; Knop D; Mueller N; Hardt C; Kreuzfelder E; Grosse-Wilde H
    J Neuroimmunol; 2006 Nov; 180(1-2):178-84. PubMed ID: 17011048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T regulatory cells lacking CD25 are increased in MS during relapse.
    Fransson M; Burman J; Lindqvist C; Atterby C; Fagius J; Loskog A
    Autoimmunity; 2010 Dec; 43(8):590-7. PubMed ID: 20370571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease.
    Trabattoni D; Saresella M; Pacei M; Marventano I; Mendozzi L; Rovaris M; Caputo D; Borelli M; Clerici M
    J Immunol; 2009 Oct; 183(8):4984-93. PubMed ID: 19794071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
    Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
    Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial cells augment the suppressive function of CD4+ CD25+ Foxp3+ regulatory T cells: involvement of programmed death-1 and IL-10.
    Bedke T; Pretsch L; Karakhanova S; Enk AH; Mahnke K
    J Immunol; 2010 May; 184(10):5562-70. PubMed ID: 20382886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy.
    Cosentino M; Zaffaroni M; Trojano M; Giorelli M; Pica C; Rasini E; Bombelli R; Ferrari M; Ghezzi A; Comi G; Livrea P; Lecchini S; Marino F
    Neuroimmunomodulation; 2012; 19(5):283-92. PubMed ID: 22472872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden.
    Feyler S; von Lilienfeld-Toal M; Jarmin S; Marles L; Rawstron A; Ashcroft AJ; Owen RG; Selby PJ; Cook G
    Br J Haematol; 2009 Mar; 144(5):686-95. PubMed ID: 19133978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: a longitudinal 1-year study.
    Aristimuño C; de Andrés C; Bartolomé M; de las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    Clin Immunol; 2010 Feb; 134(2):148-57. PubMed ID: 19900844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitudinal study.
    de Andrés C; Aristimuño C; Bartolomé M; de Las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    J Neuroimmunol; 2009 Jul; 212(1-2):112-20. PubMed ID: 19446889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A possible role of CD4+CD25+ T cells as well as transcription factor Foxp3 in the dysregulation of allergic rhinitis.
    Xu G; Mou Z; Jiang H; Cheng L; Shi J; Xu R; Oh Y; Li H
    Laryngoscope; 2007 May; 117(5):876-80. PubMed ID: 17473687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis.
    Haas J; Hug A; Viehöver A; Fritzsching B; Falk CS; Filser A; Vetter T; Milkova L; Korporal M; Fritz B; Storch-Hagenlocher B; Krammer PH; Suri-Payer E; Wildemann B
    Eur J Immunol; 2005 Nov; 35(11):3343-52. PubMed ID: 16206232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The levels of CD4+CD25+ regulatory T cells in paediatric patients with allergic rhinitis and bronchial asthma.
    Lee JH; Yu HH; Wang LC; Yang YH; Lin YT; Chiang BL
    Clin Exp Immunol; 2007 Apr; 148(1):53-63. PubMed ID: 17349011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Frisullo G; Nociti V; Iorio R; Plantone D; Patanella AK; Tonali PA; Batocchi AP
    Hum Immunol; 2010 May; 71(5):437-41. PubMed ID: 20138197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.